LEADER 00000nam  2200000 a 4500 
001    399591722    
003    OCoLC 
005    20090617134626.0 
008    090615s2008    dcu      b   f000 0 eng c 
020    9780160832406 
020    0160832403 
035    97376206 
037    552-070-39068-5|bGPO 
040    GPO|cGPO|dGPO|dMvI 
042    pcc 
043    n-us--- 
074    1019-A-01 
086 0  Y 4.C 73/8:110-87 
110 1  United States.|bCongress.|bHouse.|bCommittee on Energy and
       Commerce.|bSubcommittee on Oversight and Investigations. 
245 10 Ketek clinical study fraud :|bwhat did Aventis know? : 
       hearing before the Subcommittee on Oversight and 
       Investigations of the Committee on Energy and Commerce, 
       House of Representatives, One Hundred Tenth Congress, 
       second session, February 12, 2008. 
260    Washington :|bU.S. G.P.O. :|bFor sale by the Supt. of 
       Docs., U.S. G.P.O.,|c2008. 
300    iii, 187 p. ;|c24 cm. 
500    Shipping list no.: 2009-0323-P. 
500    "Serial no. 110-87." 
504    Includes bibliographical references. 
650  0 Telithromycin|xTesting|xCorrupt practices|zUnited States. 
650  0 Antibiotics|xTesting|xCorrupt practices|zUnited States. 
650  0 Clinical trials|xCorrupt practices|zUnited States. 
650  0 Drug approval|zUnited States. 
776 0  United States. Congress. House. Committee on Energy and 
       Commerce. Subcommittee on Oversight and Investigations.
       |tKetek clinical study fraud|hiii, 187 p.
       |w(OCoLC)399633050. 
LOCATION CALL # STATUS
 GovDocs Federal  Y 4.C 73/8:110-87    AVAILABLE